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SUMMARY. Assessment of liver fibrosis is important in
determining prognosis, disease progression and need for
treatment in patients with chronic hepatitis B (CHB). Limi-
tations to the use of liver biopsy in assessing fibrosis are
well recognized, and noninvasive tests are being increas-
ingly evaluated including transient elastography (TE) and
serum markers such as the Enhanced Liver Fibrosis (ELF)
test. We assessed performance of ELF and TE in detecting
liver fibrosis with reference to liver histology in a cohort of
patients with CHB (n = 182), and compared the perfor-
mance of these modalities. Median age was 46 and mean
AST 70 IU/L. Cirrhosis was reported in 20% of liver biop-
sies. Both modalities performed well in assessing fibrosis at
all stages. Area under receiver operator characteristic (AU-
ROC) curves for detecting METAVIR fibrosis stages F ≥ 1,
F ≥ 2, F ≥ 3 and F4 were 0.77, 0.82, 0.80 and 0.83 for
ELF and 0.86, 0.86, 0.90 and 0.95 for TE. TE performed
significantly better in the assessment of severe fibrosis
(AUROC 0.80 for ELF and 0.90 for TE, P < 0.01) and cir-
rhosis (0.83 for ELF and 0.95 for TE, P < 0.01). This study
demonstrates that ELF has good performance in detection
of liver fibrosis in patients with CHB, and when compared,
TE performs better in detection of severe fibrosis/cirrhosis.
Keywords: chronic hepatitis B, Enhanced Liver Fibrosis test,
liver fibrosis, noninvasive markers, transient elastography.
INTRODUCTION
Chronic hepatitis B (CHB) caused by infection with the
hepatitis B virus (HBV) is characterized by periods of con-
tinuous or fluctuating inflammation of the liver, leading to
fibrosis, which may remain occult, with no clinical signs
or symptoms at the time of diagnosis of CHB. Morbidity
and mortality in patients with CHB are related to persis-
tence of viral replication and the development of liver fibro-
sis that may progress to cirrhosis and its complications,
particularly portal hypertension and liver cancers including
hepatocellular cancer, and an increased risk of intra- and
extrahepatic biliary cancer [1,2]. The assessment of liver
fibrosis is therefore an essential component in the initial
evaluation of patients with CHB and informs the decision
to commence antiviral therapy. Liver fibrosis assessment
using invasive or noninvasive tests is a key feature of inter-
national guidelines [3,4]. Continued monitoring of fibrosis
is critical to determine changes in fibrosis over time and to
assess the efficacy of therapy and the necessity for inter-
ventions to manage portal hypertension and screen for
liver cancer and progression to cirrhosis.
The traditional method for assessing liver fibrosis has been
needle biopsy of the liver, however this is expensive, fre-
quently painful and potentially hazardous for the patient,
and subject to sampling error and variation in interpretation
[5,6]. While many patients with CHB can be persuaded to
undergo a first biopsy, most will be reluctant to accept sub-
sequent follow-up biopsies to evaluate disease progression or
response to treatment. Noninvasive methods of assessing
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liver fibrosis in a range of chronic liver diseases are being
explored. Principal among these are transient elastography
(TE) and serum markers, and these are now being evaluated
in patients with CHB [7–9]. The Enhanced Liver Fibrosis
(ELF) test (Siemens Healthcare Diagnostics Inc., Tarrytown,
New York, USA) is a panel of biomarkers comprising hyal-
uronic acid (HA), tissue inhibitor of matrix metalloprotein-
ase-1 (TIMP-1) and aminoterminal propeptide of
procollagen type III (PIIINP), derived from studies in patients
with a range of chronic liver diseases including CHB [10].
Previous studies comparing the performance of noninva-
sive markers of liver fibrosis in CHB have reported contra-
dictory results. Performance defined by the area under the
receiver operator curve (AUROC) of TE to identify F ≥ 2
has been reported in several studies to range from 0.61 to
0.87 [11–16].
The aim of this primary study was to evaluate and vali-
date the performance of ELF in a cohort of patients with
CHB and to compare ELF to a different noninvasive modal-
ity, TE, in the assessment of liver fibrosis defined by histo-
logical staging of liver biopsies.
MATERIALS AND METHODS
Patients
Subjects were recruited at a single Italian centre. Among
224 treatment-na€ıve patients with CHB who were consecu-
tively referred for a liver biopsy and TE evaluation to the
Liver Center, Fondazione IRCCS Ca’ Granda Ospedale Mag-
giore Policlinico, Milan [8], those with a stored serum sam-
ple available for ELF testing were included. Patients with
hepatitis C virus, hepatitis delta virus and human immuno-
deficiency virus coinfections, other concomitant liver dis-
eases, current or previous hepatic decompensation, current
or previous antiviral treatment and/or an absolute contra-
indication to liver biopsy (platelet count <60 9 109/L,
INR > 1.35) were excluded. In all patients, serum sam-
pling, liver biopsy and TE were performed on the same
day. All patients gave their written consent to the study,
which was approved by the local ethics committee.
Blood markers
Serum samples were analysed for levels of HA, TIMP-1 and
PIIINP using the proprietary assays developed for the ELF
test by Siemens Healthcare Diagnostics Inc. These assays
are magnetic particle separation immunoassays, and sam-
ples were analysed on an ADVIA Centaur immunoassay
system (Siemens Medical Solutions Diagnostics Inc., Tarry-
town, NY, USA). Results were entered into the manufac-
turer’s published algorithm to derive an ELF score.
Quantitative polymerase chain reaction amplification for
HBV DNA was performed using Amplicor HBV Monitor
(Roche Diagnostics, Branchburg, NJ, USA), and serology
for HBeAg status was assessed with standard assays, and
serum alanine aminotransferase (ALT) and aspartate trans-
aminase (AST) were measured using standard enzymatic
immunoassays.
Liver biopsy
All patients underwent an ultrasound-guided liver biopsy
with a semiautomatic modified Menghini system (16G, Bio-
Mol, Hospital Service, Pomezia, Italy, Philips iU22, Bothell,
WA, USA) to stage severity of hepatitis. All the procedures
were carried out by two highly experienced hepatologists.
Liver specimens were considered of adequate size if longer
than 2 cm. Patients with a smaller specimen underwent a
repeat procedure during the same session. Five-micron
thick sections of formalin-fixed, paraffin-embedded liver tis-
sue were stained with haematoxylin–eosin and Masson tri-
chrome, and read by a single liver pathologist blind to TE
and clinical data. Grading and staging were evaluated
according to METAVIR (staging F0 = fibrosis absent,
F1 = portal fibrosis without septa, F2 = portal fibrosis with
few septa, F3 = severe fibrosis, F4 = cirrhosis) [17].
Transient elastography
After an overnight fast, patients underwent a FibroScan
(Echosens, Paris, France) utilizing a 5-MHz ultrasound
transducer probe mounted on the axis of a vibrator that was
operated by three experienced hepatologists who were blind
to clinical, biochemical and histological data [18,19].
Briefly, mild amplitude and low-frequency vibrations
(50 Hz) are transmitted to the liver, thus inducing an elastic
shear wave propagating through the underlying liver tissue.
Velocity of the wave is directly related to tissue stiffness. The
tip of the transducer was covered with a drop of gel and
placed perpendicularly in the intercostal space with the
patient lying in dorsal decubitus with the right arm in maxi-
mal abduction. Under control time motion and A-mode, the
operator chose a liver portion within the right liver lobe at
least 6 cm thick, free of large vascular structures and gall-
bladder. Ten successful acquisitions were performed on each
patient. The success rate (SR) was calculated as the ratio of
the number of successful acquisitions over the total number
of acquisitions. The median value, expressed in kPa, was
kept as representative of the liver stiffness. The manufac-
turer recommends that liver stiffness measurements are con-
sidered reliable using the following criteria: (i) number of
valid acquisitions at least 10, (ii) SR at least 60% and an in-
terquartile range of the median of 30% or less.
Statistical analysis
Statistical analyses were performed using SPSS for Win-
dows (version 19, SPSS Inc, Chicago, IL, USA), Stata Sta-
tistical Software (StataCorp 2007. Release 10. College
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Station, TX, USA: StataCorp LP) and R (version 2.11.1, R
Foundation for Statistical Computing, Vienna, Austria).
Median values and interquartile ranges for each diagnostic
test were determined for each fibrosis stage. The diagnostic
performances of ELF and TE were assessed by deriving the
area under receiver operator characteristic (AUROC)
curves. AUROC and 95% confidence intervals of AUROC
were calculated. Comparisons of AUROC values for ELF
and TE were determined for each stage of fibrosis using the
DeLong method to calculate the chi-squared value for the
comparison and expressed as the significance of difference
(P value) [20].
Optimal cut-off values for discriminating positive and
negative cases at each fibrosis stage for ELF and TE were
determined by identifying the point of maximum sensitivity
and specificity on the ROC curve, and sensitivity, specific-
ity, positive and negative predictive values (PPV and NPV),
and positive and negative likelihood ratios calculated. The
clinical utility of each test was evaluated by analysing per-
formance by selecting an upper threshold with high speci-
ficity, therefore high PPV to ‘rule in’ fibrosis and a low
threshold with high sensitivity and therefore high NPV to
‘rule out’ fibrosis.
Logistic regression analysis was conducted to further
investigate the relationship both between individual modal-
ities and fibrosis, and within a model combining both ELF
and TE.
Recently, several methodological issues have been raised
in relation to the application of ROC curve analysis to com-
pare noninvasive tests with liver biopsy. The spectrum
effect (the differences in the distributions of fibrosis stages
in the sample and reference populations) may result in the
performance of a noninvasive test varying between the
populations giving rise to apparent differences in perfor-
mance of tests between different sample populations. In
addition, ROC analysis assumes the reference standard to
be binary, whereas the METAVIR scoring system employs a
five-stage ordinal scale. To overcome these potential flaws,
the difference between advanced and nonadvanced (DANA)
fibrosis stages [21] and Obuchowski [22] methods of cor-
recting for spectrum effect were applied. The results are
presented of applying the Obuchowski measure using previ-
ously described penalty functions [23] to correct for the
degree of difference between the histological stages ascribed
by pathological staging and conversion of ELF test scores.
RESULTS
Of the 224 subjects consecutively recruited, 188 had a
stored serum sample. TE acquisition was unsuccessful in
six of these subjects (3%); therefore, paired ELF and TE
data were available for 182 subjects. Replacing values for
missing TE results by both imputation of simple mean and
expectation maximization methods did not change the sig-
nificance of difference between ELF and TE in ROC analy-
sis, therefore, only subjects with paired results were used
in the analysis.
Baseline characteristics are shown in Table 1. All patients
had a diagnosis of CHB and were treatment-na€ıve. Median
age was 46 years, 71% were male, and 71% were HBeAg
negative. 79 (43%) were overweight (BMI ≥ 25 kg/m2).
Biopsies reported any fibrosis (METAVIR F ≥ 1) in 90.1%,
moderate fibrosis (METAVIR F2) in 25.8% and severe fibro-
sis/cirrhosis (METAVIR F ≥ 3, equivalent to Ishak stage
4–6) in 36.8%.
Both ELF and TE discriminated different fibrosis stages
well with linear progression (Fig. 1), and both modalities
performed well in predicting fibrosis stage. The AUROC for
the diagnosis of each stage of fibrosis for ELF and TE is
shown in Table 2. The AUROC for the diagnosis of any
fibrosis for ELF and TE was 0.77 and 0.86, respectively
(P = 0.09). The AUROC for the diagnosis of severe fibrosis/
Table 1 Baseline subject characteristics
Characteristic All subjects
By METAVIR stage
F0 F1 F2 F3 F4
Number of
subjects
182 18 (9.9) 50 (27.5) 47 (25.8) 31 (17.0) 36 (19.8)
Age, median
(range)
46 (18–67) 32.5 (21–54) 44.0 (18–65) 46 (20–67) 55 (27–65) 50 (29–65)
AST (IU/L),
mean (SD)
69.7 (64.1) 47.3 (31.9) 49.2 (31.6) 66.4 (38.5) 86.6 (71.1) 97.1 (105.5)
ALT (IU/L),
mean (SD)
110.3 (103.4) 86.4 (78.1) 86.7 (72.0) 110.2 (68.0) 148.1 (167.0) 122.6 (112.4)
HBeAg + (n) 53 7 12 10 12 12
 (n) 129 11 38 37 19 24
HBV DNA, log10
mean
7.96 7.97 7.82 8.07 7.93 7.98
AST, aspartate transaminase; ALT, alanine aminotransferase; SD, standard deviation; HBV, hepatitis B virus.
© 2013 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
432 P. M. Trembling et al.
cirrhosis for ELF and TE was 0.80 and 0.90, respectively
(P < 0.01). The AUROC for the diagnosis of cirrhosis
(METAVIR F4) was 0.83 and 0.95, respectively (P < 0.01).
Table 3 shows the sensitivities, specificities, predictive
values and diagnostic odds ratios of ELF and TE predicting
severe fibrosis/cirrhosis and cirrhosis. If two thresholds
with high sensitivity and specificity are used to ‘rule in’
fibrosis (upper threshold with high specificity, therefore
high positive predictive value) or ‘rule out’ fibrosis (lower
threshold with high sensitivity, therefore, high negative
predictive value), the clinical utility of each modality can
be evaluated. For example, using ELF to identify severe
fibrosis at data-derived thresholds of 9.08 and 9.94 (sensi-
tivity and specificity of 85%, respectively), 60% of patients
would have correctly avoided liver biopsy and 16% would
have incorrectly avoided biopsy. 24% would have had an
indeterminate result – a value between the thresholds.
Using TE to identify severe fibrosis with thresholds of 8.75
and 8.95 (sensitivity and specificity of 85%, respectively)
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Fig. 1 Box plots showing median and quartiles for (a) TE
and (b) ELF scores for diagnosing METAVIR fibrosis stages.
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would have resulted in biopsy correctly being avoided in
82% and incorrectly avoided in 15%, with an indetermi-
nate result in 3%, shown in Fig. 2 and in Table S1. A
model for predicting any fibrosis is also shown. At higher
sensitivity and specificity, the proportion avoiding biopsy
decreases. For example, if sensitivity and specificity thresh-
olds are increased to 90%, the proportion of incorrectly
classified cases (i.e. the false positive and false negative
rates) substantially decreases to around 10% for both
modalities for diagnosis of both severe and any fibrosis.
However, this is at the cost of increased proportions of
indeterminate cases.
Logistic regression analysis found that in a model com-
bining both modalities, in the prediction of METAVIR
F ≥ 1 and F4, ELF was a nonsignificant predictor. In the
prediction of F ≥ 2 and F ≥ 3, ELF significantly improved
the prediction of fibrosis when combined with TE. Respec-
tive ELF and TE odds ratios in the combined models were
as follows: 1.45 (95% CI 0.75–2.83) and 1.99 (1.31–
3.02), 2.47 (1.55–3.94) and 1.54 (1.25–1.90), 1.61
(1.03–2.51) and 1.55 (1.31–1.83), 1.32 (0.75–2.32) and
1.44 (1.23–1.68) for F ≥ 1, F ≥ 2, F ≥ 3 and F4, respec-
tively (Table S2). Combining the two tests results in AU-
ROC values of 0.87, 0.88, 0.90 and 0.95 for diagnosis of
F ≥ 1, F ≥ 2, F ≥ 3 and F4 stages, respectively.
A subanalysis of the performance in HBeAg-negative
patients showed similar performance of ELF and TE to that
for the whole cohort. AUROC values for ELF and TE for
F ≥ 1, F ≥ 2, F ≥ 3 and F4 stages were 0.71, 0.80, 0.79,
0.81 and 0.81, 0.83, 0.90, 0.95, respectively, with a sig-
nificant difference in performance at F ≥ 3 and F4.
The effect of ALT on test performance was assessed.
Diagnostic accuracy appears to be maintained with both
modalities when ALT is 3 or 5 times above the upper limit
of normal (ULN). In the diagnosis of severe fibrosis, both
modalities maintained their performance in all categories
of ALT. The AUROC values indicate that in the diagnosis
of any fibrosis, ELF is less accurate when ALT is below the
ULN compared with when ALT is above the ULN, and
accuracy of TE improves when ALT is below the ULN. The
95% confidence interval for ELF in diagnosing any fibrosis
is very large in this small cohort. When ALT is above 3 or
Table 3 Diagnostic performance indices for ELF and TE in the identification of severe fibrosis (F3,4) and cirrhosis (F4) at a
range of thresholds
Modality Threshold Sensitivity% Specificity% PPV% NPV% LR + LR  DOR
Severe fibrosis (prevalence = 37%)
ELF 8.02 96 17 40 86 1.10 0.24 4.58
8.45 93 41 48 90 1.58 0.17 9.29
8.96 85 56 53 86 1.93 0.27 7.15
9.39 73 70 58 82 2.43 0.39 6.23
9.88 60 83 67 78 3.53 0.48 7.35
10.41 45 95 83 75 9.00 0.58 15.52
TE 6.85 96 50 52 95 1.92 0.08 24.00
7.70 91 60 57 92 2.28 0.15 15.20
8.45 88 77 69 92 3.83 0.16 23.94
9.35 79 87 78 88 6.08 0.24 25.33
10.15 64 90 80 81 6.40 0.40 16.00
11.95 57 96 88 79 14.25 0.45 31.67
Cirrhosis (prevalence = 20%)
ELF 8.61 94 39 28 97 1.54 0.15 10.27
9.43 72 64 34 90 2.00 0.44 4.55
9.66 69 72 38 90 2.46 0.43 5.72
9.99 67 81 47 91 3.53 0.41 8.61
10.34 61 87 54 90 4.69 0.45 10.42
10.68 44 95 70 87 8.80 0.59 14.92
TE 9.70 94 80 54 98 4.70 0.08 58.75
10.30 89 86 62 97 6.36 0.13 48.92
11.85 83 90 67 96 8.30 0.19 43.68
12.95 75 92 71 94 9.38 0.27 34.74
14.15 61 95 74 91 12.20 0.41 29.76
15.45 50 95 72 88 10.00 0.53 18.87
PPV, positive predictive value; NPV, negative predictive value; LR +, positive likelihood ratio; LR , negative likelihood
ratio; DOR, diagnostic odds ratio.
© 2013 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
434 P. M. Trembling et al.
5 times the ULN, diagnostic accuracy appears to be main-
tained with both modalities (Table S3).
DISCUSSION
This study has demonstrated that the ELF test accurately
assesses liver fibrosis severity in patients with CHB. Com-
parison of TE and ELF demonstrated good performance of
both modalities, with TE performing significantly better in
the identification of severe fibrosis/cirrhosis.
The ELF test has been validated in external disease-spe-
cific cohorts of patients with nonalcoholic fatty liver dis-
ease, primary biliary cirrhosis and chronic hepatitis C [24–
29]. It predicts liver-related outcomes at 7 years at least as
well as biopsy, with a unit change in ELF associated with
a doubling of risk [30]. Of the 25 patients with CHB fol-
lowed up for over 7 years in that study, 2 died of a liver-
related cause and one experienced a nonfatal liver-related
outcome by 7 years (median for the whole cohort) after
biopsy and ELF test. In all 3 cases, the incident ELF score
exceeded 7.8. The median ELF score was 8.63 for the
whole cohort of CHB patients that were followed up.
This study reports the external validation of the ELF test
in subjects with CHB. Performance in patients with CHB in
the original cohort (n = 44) was good at all fibrosis stages
and maintained in this validation cohort. Logistic regres-
sion, which included age and simple biochemical parame-
ters (AST, ALT), did not improve performance. These data
suggest a role for ELF in the assessment of patients with
CHB and in informing the decision-making process when
antiviral therapy is being considered.
A recent study [31] reporting the performance of ELF in
58 patients with CHB used the published algorithm [24]
but not the immune assays that have been specifically
developed for the ELF test. AUROC values for predicting
Ishak fibrosis stages 1–6 and 2–6 (equivalent to METAVIR
F ≥ 1) were 0.66 and 0.59, respectively, lower than the
values we report. AUROC for predicting Ishak stages 3–6
was 0.83, similar to our findings. The inferior performance
of the test in this cohort is likely to be attributable to the
use of assays that were not specifically developed for the
ELF test and failure to use the appropriate autoanalyser.
Recently, the performance of ELF and TE has been stud-
ied in a cohort of Asian subjects with CHB [32]. AUROC
values for predicting F ≥ 2, F ≥ 3 and F4 were 0.90, 0.86
and 0.86 for ELF and 0.94, 0.96 and 0.96 for TE, respec-
tively. TE was significantly better than ELF for predicting
F ≥ 3 and F4.
In the present study, TE performed as well or better than
in other studies in patients with CHB. For example, in the
detection of F4 fibrosis, AUROC values in other studies
range from 0.88 [11] to 0.94 [33]. A meta-analysis of
noninvasive tests for liver disease severity in nonalcoholic
fatty liver disease [34] found that the collective perfor-
mance of TE in detecting F ≥ 2 and F ≥ 3 fibrosis was
0.84 (95% CI 0.79–0.90) and 0.94 (95% CI 0.86–0.99),
respectively. Regression analysis found that success was
unaffected by the severity of inflammation or steatosis, but
obesity was an independent predictor of failure of TE.
The rate of TE failure (3%) was very low in this study; a
major review of clinical performance found a failure rate of
18.9% [35]. Studies investigating TE in patients with CHB
report success rates for acquiring valid TE results ranging
between 79% and 99.6% [11,16,35–39]. TE reproducibil-
ity has been shown to be excellent for both inter-and intra-
observer agreement, but this is reduced at lesser stages of
fibrosis and in patients with steatosis, high body mass
index and in particular waist circumference [40,41]. All 6
patients in our study excluded due to TE failure were over-
weight (n = 2) or obese (n = 4).
Both ELF and TE represent alternative and potentially
complimentary approaches to assessing liver fibrosis and
are associated with minimal discomfort and hazard to the
patient when compared with biopsy. Logistic regression
analysis suggests that the performance of ELF is improved
with the addition of TE, although TE does not improve
with the addition of ELF.
Both modalities track fibrosis stage linearly, with TE
having superior discrimination and closer correlation with
histological staging, particularly at higher fibrosis stages.
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Fig. 2 Clinical utility model for ELF and TE predicting
(a) any fibrosis and (b) severe fibrosis with sensitivity and
specificity of 85%.
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The performance of TE predicting F ≥ 2 fibrosis in this
study was superior to most of the previous studies assess-
ing TE in CHB. The diagnostic performance of each modal-
ity was evaluated at various sensitivities and specificities;
the median diagnostic odds ratio for ELF for detecting
severe fibrosis between sensitivity and specificity of 95%
was 7.3 and for TE 24.0. Clinical utility modelling supports
a role for these modalities in the assessment of patients
and in treatment decisions.
Applying previously published thresholds to our data
allows for some generalizability of the model. Recent stud-
ies investigating ELF and TE both in a heterogeneous popu-
lation [42] and in CHB [32] did not report dual thresholds,
making comparison difficult. However, using thresholds
reported in separate studies allows some comparisons to be
drawn. A study of TE in CHB [8] reported that cut-off val-
ues of 9.4 and 6.2 which had sensitivity and specificity of
>90% ruled in and ruled out F ≥ 2 in 56% of cases, with
90% accuracy. Applying these thresholds to our data, 57%
of patients would have F ≥ 2 ruled in or ruled out, with
91% accuracy. Data from patients with chronic hepatitis C
[27] found that using ELF cut-off values of 9.59 and
10.22, with sensitivity and specificity of 85%, 81% of
patients could avoid biopsy by having severe fibrosis
(F ≥ 3) ruled in or ruled out, with 81% accuracy. Applying
these thresholds to our data, 77% of patients would avoid
biopsy, with 86% accuracy.
Using the DANA method to calculate the adjusted uni-
form AUROC, diagnostic performance increased at all fibro-
sis stages with both modalities. This method assumes equal
prevalence in all fibrosis stages, which may not be reflec-
tive of true prevalence and may overestimate prevalence at
the extremes of fibrosis stage. Further, the coefficient in the
equation was developed using a population of patients with
chronic hepatitis C, and with a different noninvasive test,
although it has been employed subsequently in a cohort of
CHB patients [43]. Further validation of this method is
required. Adjustment using the Obuchowski method
showed that the overall mean accuracy (unweighted Obu-
chowski measure) was 0.91 for ELF and 0.95 for TE. For
diagnosis between F3 and F4, performance was 0.59 for
ELF and 0.73 for TE (Table S4).
Strengths of this study include the method of data collec-
tion. Liver biopsy, TE and serum sampling were all per-
formed on the same day. ELF tests were performed in one
central laboratory, ensuring quality control and consis-
tency. It is important to note that the present study used
the proprietary ELF assays in accordance with the manu-
facturer’s instructions rather than a ‘homebrew’ combina-
tion of substitute assays performed on other platforms as
reported in other studies [31]. There are several potential
limitations to this study. The low failure rate of TE in this
study was at odds with much larger reports of clinical
practice. The relatively high prevalence of fibrosis in this
cohort means that the findings may not be reliably applied
to lower prevalence populations such as the primary care
setting, where the positive predictive value of the test will
be lower.
This study has demonstrated that the performance of
ELF in detection of liver fibrosis in subjects with CHB is
good and is reproducible. Both ELF and TE perform well in
the prediction of fibrosis at all stages, with TE superior at
detecting severe fibrosis and cirrhosis in this cohort that
contained a high prevalence of severe fibrosis. Further
analyses in cohorts of subjects with CHB are required.
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